BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35053517)

  • 1. Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network.
    Romeo C; Le Saux O; Jacobs M; Joly F; Ferron G; Favier L; Fumet JD; Isambert N; Colombo PE; Sabatier R; Bastide L; Charreton A; Devouassoux-Shisheboran M; Gertych W; Dubot C; Bello Roufai D; Bataillon G; Berton D; Kalbacher E; Pautier P; Pomel C; Cornou C; Treilleux I; Lardy-Cleaud A; Ray-Coquard I
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.
    Cicin İ; Özatlı T; Türkmen E; Özturk T; Özçelik M; Çabuk D; Gökdurnalı A; Balvan Ö; Yıldız Y; Şeker M; Özdemir N; Yapar B; Tanrıverdi Ö; Günaydin Y; Menekşe S; Öksüzoğlu B; Aksoy A; Erdogan B; Bekir Hacıoglu M; Arpaci E; Sevinç A
    Balkan Med J; 2016 Sep; 33(5):517-524. PubMed ID: 27761279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
    Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
    Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
    Berton-Rigaud D; Devouassoux-Shisheboran M; Ledermann JA; Leitao MM; Powell MA; Poveda A; Beale P; Glasspool RM; Creutzberg CL; Harter P; Kim JW; Reed NS; Ray-Coquard I
    Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S55-60. PubMed ID: 25341582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
    Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
    Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine and Ovarian Carcinosarcomas: Do They Behave Similarly?
    Ureyen I; Karalok A; Cirik DA; Tasci T; Gokce ZK; Duzguner IB; Tulunay G; Turan T
    J Obstet Gynaecol Can; 2017 Jul; 39(7):559-563. PubMed ID: 28625283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
    Makker V; Abu-Rustum NR; Alektiar KM; Aghajanian CA; Zhou Q; Iasonos A; Hensley ML
    Gynecol Oncol; 2008 Nov; 111(2):249-54. PubMed ID: 18755503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
    Galaal K; van der Heijden E; Godfrey K; Naik R; Kucukmetin A; Bryant A; Das N; Lopes AD
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD006812. PubMed ID: 23450572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gynecological carcinosarcomas: Overview and future perspectives.
    Collet L; González López AM; Romeo C; Méeus P; Chopin N; Rossi L; Rowinski E; Serre AA; Rannou C; Buisson A; Treilleux I; Ray-Coquard I
    Bull Cancer; 2023 Nov; 110(11):1215-1226. PubMed ID: 37679206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.
    Hanvic B; Lecuru F; Vanacker H; Pautier P; Narducci F; Cherifi F; Floquet A; Angeles MA; Berton D; Pomel C; Kalbacher E; Provansal M; Fernandez Y; Rouge TM; Roméo C; Laas E; Morice P; Hudry D; Meriaux E; Guyon F; Illac-Vauquelin C; Selle F; Meeus P; Genestie C; Salleron J; Ray-Coquard I
    Gynecol Oncol; 2023 Jul; 174():190-199. PubMed ID: 37210929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery.
    Matsuo K; Johnson MS; Im DD; Ross MS; Bush SH; Yunokawa M; Blake EA; Takano T; Klobocista MM; Hasegawa K; Ueda Y; Shida M; Baba T; Satoh S; Yokoyama T; Machida H; Ikeda Y; Adachi S; Miyake TM; Iwasaki K; Yanai S; Takeuchi S; Nishimura M; Nagano T; Takekuma M; Shahzad MMK; Pejovic T; Omatsu K; Kelley JL; Ueland FR; Roman LD
    J Surg Oncol; 2018 Mar; 117(3):488-496. PubMed ID: 29044542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
    Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
    Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy in uterine carcinosarcoma: Comparison of a doublet and a triplet chemotherapeutic regimen.
    Maheshwari U; Rajappa SK; Talwar V; Goel V; Dash PK; Sharma M; Goyal P; Jain P; B Koyyala VP; Doval DC
    Indian J Cancer; 2021; 58(2):179-184. PubMed ID: 33753600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
    Galaal K; Godfrey K; Naik R; Kucukmetin A; Bryant A
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006812. PubMed ID: 21249682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
    Powell MA; Filiaci VL; Hensley ML; Huang HQ; Moore KN; Tewari KS; Copeland LJ; Secord AA; Mutch DG; Santin A; Warshal DP; Spirtos NM; DiSilvestro PA; Ioffe OB; Miller DS
    J Clin Oncol; 2022 Mar; 40(9):968-977. PubMed ID: 35007153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
    García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
    Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy.
    Athavale R; Thomakos N; Godfrey K; Kew F; Cross P; de Barros Lopes A; Hatem MH; Naik R
    Int J Gynecol Cancer; 2007; 17(5):1025-30. PubMed ID: 17466043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy and prognosis in uterine carcinosarcoma.
    Chiang CY; Huang HJ; Chang WY; Yang LY; Wu RC; Wang CC; Tung HJ; Chao A; Lai CH
    J Formos Med Assoc; 2021 Nov; 120(11):1977-1987. PubMed ID: 33992491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.